Clinical Trials of Ewing Sarcoma

Executive Summary

Clinical trials are considered a better method for treating Ewing sarcoma. The evaluation of new drugs, different combinations of treatments, new approaches to radiation therapy or surgery, and new therapies are integrated into clinical trials of Ewing sarcoma. New treatments with better efficacy and safety are the outcome of a clinical trial. The results of the clinical trials have been effective in reducing the symptoms and side effects during the treatment. Volunteers or patients willing to participate in the clinical trials should communicate with their doctor and healthcare team, and research expertise to make well decided informed choices regarding participating in the problem while signing informed consent. The volunteers willingly participate as they know the studies are a way to help advance the treatment of Ewing sarcoma. Eligibility criteria for Ewing sarcoma clinical trials ensure that the participants are safe, bound to no ill effects, and well-structured research. People who take part in clinical trials of Ewing sarcoma may withdraw their participation at any moment in time due to any personal or medical conditions. It may be because the treatment is not working or giving the desired results, including severe risks and side effects.

Clinical Trials of Ewing Sarcoma

On the path to finding different ways to treat cancer, various research and trials have been carried out to find safe and effective treatments other than the standard ones. Every drug that is used now was once tested in clinical trials. The clinical studies mainly focus on finding a safe, effective, and better treatment or diagnostic procedure. They evaluate new chemotherapy or radiotherapy drugs for better treatment of cancer ​1​.

Taking part in clinical trials can benefit people by receiving treatment before it is available. As the coin has two sides, there are some risks with the clinical trials, including its side effects and the possibility of new clinical trials not working. Clinical trials are also conducted on drugs and other therapies that can relieve the symptoms and side effects of treatments like chemotherapy, radiotherapy, etc. ​2​. People are strongly encouraged to talk with their health care team about the pros and cons of joining a specific study.

Participating in clinical trials can have many reasons. For some people, taking part in a clinical trial is the only option to receive the best treatment for the type of cancer. Because standard treatments are not perfect, people are willing to face the uncertainty and challenges of a clinical trial to seek a better result. 

Insurance and the costs of clinical trials change depending upon location and by study. Some of the expenses from participating in the clinical trial are reimbursed in several programs.

Clinical trials also have specific “eligibility criteria” rules that help research patients be safe. You and your research team carefully review these criteria together. People participating in a clinical trial can stop participating at any time for any medical or personal reasons. The reasons may include that the new treatment is not working or has severe side effects. Experts keep an eye on clinical trials for any problems with each study.

Clinical trials play a crucial role in advancing the understanding and treatment of Ewing sarcoma. These trials aim to evaluate new treatments, treatment combinations, or treatment strategies to improve outcomes for individuals with Ewing sarcoma. Clinical trials can also investigate new diagnostic techniques, risk assessment tools, and supportive care interventions. Here are a few examples of clinical trials that have been conducted or are currently ongoing for Ewing sarcoma:

  1. EURO-E.W.I.N.G. 2012 Trial: This international, multicenter trial evaluated the efficacy and safety of a risk-adapted treatment approach for patients with localized Ewing sarcoma. The trial aimed to assess the outcomes of combining different chemotherapy agents, including ifosfamide, etoposide, and vincristine, with or without additional treatments such as high-dose chemotherapy and stem cell transplantation.
  2. COG AHEP1531 Trial: This ongoing trial conducted by the Children’s Oncology Group (COG) is investigating the use of immunotherapy in combination with standard chemotherapy for patients with high-risk or metastatic Ewing sarcoma. The trial is evaluating the addition of the immunotherapy agent nivolumab to standard chemotherapy to improve outcomes in this patient population.
  3. Ewing 2008 Trial: This European trial aimed to assess the role of interval compressed chemotherapy and surgery in localized Ewing sarcoma. The trial investigated the outcomes of a treatment regimen involving shorter intervals between chemotherapy cycles and the timing of surgical resection.
  4. EuroEwing 2012 Intensification Trial: This ongoing European trial is investigating the effectiveness of intensified treatment with high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk Ewing sarcoma. The trial aims to improve outcomes for patients at higher risk of relapse or with metastatic disease.

It’s important to note that clinical trials have specific eligibility criteria, and participation is voluntary. If you or someone you know is interested in participating in a clinical trial, it is recommended to consult with a healthcare provider or contact specialized cancer centers and research institutions. These organizations can provide information on available clinical trials, eligibility criteria, potential benefits and risks, and how to enroll in a trial.


  1. 1.
    Anderson WJ, Doyle LA. Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours. Histopathology. Published online January 12, 2021:644-657. doi:10.1111/his.14265
  2. 2.
    Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. European Journal of Cancer. Published online September 2016:91-101. doi:10.1016/j.ejca.2016.06.009